Effects of rnitornycin C on radiation-induced cell death in human cervical squamous cell carcinomas

In order to find an effective protocol for chemoradiotherapy with mitomycin C (MMC) for advanced cervical cancer patients, effects of both MMC and irradiation on chemoradiosensitivity were examined using the radiosensitive human cervical squamous cell carcinoma cell line ME180. MMC and low doses of irradiation did not affect radiosensitivity of the cells. A high dose of gamma-ray irradiation (10 Gy) significantly reduced MMC sensitivity of the cells. All of the four post-irradiation surviving subclones that were established from repetitively irradiated ME180 cells, demonstrated significantly higher MMC sensitivity than that of the non-irradiated parent cells. However, there was no difference in MMC sensitivity among three groups of irradiated cells; (1) cells treated with MMC eight hours before irradiation, (2) cells concurrently treated with MMC and irradiation and (3) cells treated with MMC eight hours after irradiation. These results indicate that MMC injections after completion of radiotherapy may be a better therapy than concurrent chemoradiotherapy with MMC.

Mitomycin C; Chemoradiotherapy; Cervical cancer

[1] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer". New Engl. J. Med., 1999, 340, 1137.

[2] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A. et al.: "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer". New Engl. J Med., 1999, 340, 1144.

[3] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hanmgan E.V., Fowler W.C. Jr. et al.: "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southeast Oncology Group Study". J. Clin. Oncol., 1999, 17, 1339.

[4] Keys H.M., Bundy B.N., Stehman F.B., Muderspach LL, Chafe W.E., Suggs C.L. 3rd et al.: "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma". New Engl. J. Med., 1999, 340, 1154.

[5] Peters WA. 3rd, Liu P.Y., Barrett R.J. 2nd, Stock R.J., Monk BJ., Berek J.S. et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oneal., 2000, 18, 1606.

[6] Roberts K.B., Urdaneta N., Vera R., Vera A., Gutierrez E., Aguilar Y. et al.: "Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix". Int. J. Cancer, 2000, 90, 206.

[7] Lorvidhaya V., Chitapanarux I., Sangruchi S., Lertsanguansinchai P., Kongthanarat Y., Tangkaratt S. et al.: "Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial". Int. J. Rad. Oncol. Biol. Phys., 2003, 55, 1226.

[8] Eifel P.J., Winter K., Morris M., Levenback C., Grigsby P.W., Cooper J. et al.: "Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG)90-0l". J. Clin. Oneal., 2004, 22, 872.

[9] Tabata T., Takeshima N., Nishida H., Hirai Y., Hasumi K.: "A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapy versus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix". Anticancer Res., 2003, 23, 2885.

[10] Christie D.R., Bull C.A., Gebski V., Langlands A.O.: "Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer". Radiother. Oncol., 1995, 37, 181.

[11] Smid L., Lesnicar H., Zakotnik B., Soba E., Budihna M., Furlan L. et al.: "Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer, preliminary report". Int. J. Rad. Oncol. Biol. Phys., 1995, 32, 769.

[12J Rakovitch E., Fyles A.W., Pintilie M., Leung P.M.: "Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix". Int. J. Rad. Oneal. Biol. Phys., 1997, 38, 979.

[13] Zakotnik B., Smid L., Budihna M., LeSnicar H., Soba E., Furlan L. et al.: "Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report". Int. J. Rad. Oncol. Biol. Phys., 1998, 41, 1121.

[14] Dobrowsky W., Naude J.: "Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers". Radiotha Oncol., 2000, 57, 119.

[15] Smid L., Budihna M., Zakotnik B., Soba E., Strojan P., Fajdiga I et al.: "Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head and neck carcinoma". Int. J. Rad. Oncol. Biol. Phys., 2003, 56, 1055.

[16] Lancillotti, F., Giandomenico, V., Affabris, E., Fiorucci, G., Romeo, G., Rossi G.B.: "Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells". Cancer Res., 1995, 55, 3158.

[17] Umesaki N., Fujii T., Nishimura R., Tanaka T., Nishida M., Fushiki H. et al.: "Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study". Gynecol. Oneal., 2004, 95, 127.